Clinical trial · Observational
Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy is one of the main treatments for locally advanced esophageal carcinoma (EC). The accuracy of the existing imaging methods in diagnosing and predicting therapeutic efficacy is disappointing, which increases the difficulty in clinical decision-making. In this study, based on a continuous cohort of EC treated with radiotherapy, the clinical and pathological factors of the patients are used to classify them into the appropriate therapeutic group. By multiple liquid biopsy technologies, combining with radiomics, we intend to construct prediction models of prognosis, therapeutic effect and toxicity. The aim of this RWS is to provide appropriate individualized regimen, further optimize the treatment mode based on precision radiotherapy and improve the outcome and quality of life of EC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3DCRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 1-, 2-, 3-year overall survival
- timeFrame
- From treatment initiation to death from any cause or censor, assessed up to 36 months
- description
- Overall survival
Secondary outcomes (6)
- measure
- 1-, 2-, 3-year progression-free survival
- timeFrame
- From treatment initiation to first documented progression or death or censor, assessed up to 36 months
- description
- Progression-free survival
- measure
- Rate of acute toxicity (any and above grade 3)
- timeFrame
- From enrollment to 3 months after treatment
- description
- Toxicities according to CTCAE criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Pathology proved esophageal cancer * ECOG PS ≤3 * Signed Informed consent Exclusion Criteria: * Pregnant and lactating women * Others that researchers consider inappropriate
References
Publications (0)
Data not yet available